Related Experiment Video
Updated: May 21, 2026
Selective Depletion of Microglia from Cerebellar Granule Cell Cultures Using L-leucine Methyl Ester
Published on: July 7, 2015
Neuroprotective effect of methyl lucidone against microglia-mediated neurotoxicity
Yanji Cui1, Jinji Wu, Sung-Cherl Jung
1Department of Physiology, Jeju National University School of Medicine, 66 Jejudaehakno, Jeju-si, Jeju-do 690-756, Republic of Korea.
Abstract:
Excessive microglial activation-mediated neurotoxicity has been implicated in playing a crucial role in the pathogenesis of stroke and neurodegenerative diseases. Therefore, much attention has been paid to therapeutic strategies aimed at suppressing neurotoxic microglial activation. The microglial regulatory mechanism of methyl lucidone, a cyclopentenedione isolated from the stem bark of Lindera erythrocarpa Makino, was investigated in the present study. Methyl lucidone treatment (0.1-10 μM) significantly inhibited lipopolysaccharide (LPS, 100 ng/ml, 24 h)-stimulated nitric oxide (NO) production in a dose-dependent manner in both primary cortical microglia and BV-2 cell line. Moreover, it strongly inhibited LPS-stimulated secretion of pro-inflammatory cytokines, such as interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α). Methyl lucidone treatment markedly induced down-regulation of LPS-induced nuclear translocation of nuclear factor κB (NF-κB) through preventing the degradation of the inhibitory protein IκBα. In addition, phosphorylation of Akt and mitogen-activated protein kinases (MAPKs) such as extracellular signal-regulated kinase (ERK) and p38 kinases were also suppressed by methyl lucidone. The cell viabilities of HT-22 neurons were significantly attenuated by treatment of the conditioned media containing neurotoxic secretary molecules from LPS-stimulated microglia. However, methyl lucidone significantly blocked neuronal cell death induced by microglial conditioned media. These neuroprotective effects of methyl lucidone were also confirmed in a neuron-microglia co-culture system using EGFP-transfected B35 neuroblastoma cell line. Taken together, these results suggest that methyl lucidone may have a neuroprotective potential via inhibition of neurotoxic microglial activation implicated in neurodegeneration.
Insights
Methyl lucidone, a compound from Lindera erythrocarpa Makino, suppresses harmful microglial activation. This natural compound shows neuroprotective potential by reducing neuroinflammation and preventing neuronal death in models of neurodegeneration and stroke.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Excessive microglial activation contributes to neurotoxicity in stroke and neurodegenerative diseases.
- Targeting microglial activation is a key therapeutic strategy for neuroprotection.
Purpose of the Study:
- To investigate the microglial regulatory mechanism of methyl lucidone, a compound isolated from Lindera erythrocarpa Makino.
- To evaluate the potential neuroprotective effects of methyl lucidone against neurotoxicity mediated by microglial activation.
Main Methods:
- Methyl lucidone's effect on lipopolysaccharide (LPS)-stimulated nitric oxide (NO) and pro-inflammatory cytokine (IL-6, TNF-α) production in microglia (primary cortical and BV-2 cell line) was assessed.
- The impact of methyl lucidone on LPS-induced nuclear factor κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways was examined.
- Neuroprotective effects were evaluated using conditioned media from LPS-stimulated microglia on neuronal cell viability (HT-22) and in a neuron-microglia co-culture system.
Main Results:
- Methyl lucidone dose-dependently inhibited LPS-induced NO production and secretion of IL-6 and TNF-α in microglia.
- Methyl lucidone suppressed LPS-induced NF-κB nuclear translocation by preventing IκBα degradation and inhibited Akt/MAPK phosphorylation.
- Methyl lucidone significantly protected neurons from cell death induced by conditioned media from activated microglia.
Conclusions:
- Methyl lucidone exhibits anti-neuroinflammatory properties by inhibiting microglial activation.
- Methyl lucidone demonstrates significant neuroprotective effects, suggesting its potential as a therapeutic agent for neurodegenerative diseases and stroke.
